A Bayesian Method Based on Clotting Factor Activity for the Prediction of Maintenance Warfarin Dosage Regimens
暂无分享,去创建一个
[1] M S Leaning,et al. Validation of an algorithm for oral anticoagulant dosing and appointment scheduling. , 1995, Clinical and laboratory haematology.
[2] E. Chan,et al. Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic‐pharmacodynamic model , 1994, Clinical pharmacology and therapeutics.
[3] S. Doi,et al. Pharmacodynamic optimization of warfarin therapy , 1994, Clinical pharmacology and therapeutics.
[4] M. Grind,et al. Method for studying drug‐warfarin interactions , 1993, Clinical pharmacology and therapeutics.
[5] Malcolm Rowland,et al. Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults , 1993 .
[6] L. Poller,et al. Prospective comparative study of computer programs used for management of warfarin. , 1993, Journal of clinical pathology.
[7] M. Narayanan,et al. A Genetic Algorithm to Improve a Neural Network to Predict a Patient’s Response to Warfarin , 1993, Methods of Information in Medicine.
[8] H. Chrystyn,et al. BAYESIAN DERIVED PHARMACOKINETIC/PHARMACODYNAMIC VARIABLES FROM WARFARIN THERAPY , 1990 .
[9] G. Raskob,et al. Predicting the Daily Prothrombin Time Response to Warfarin , 1990, Therapeutic drug monitoring.
[10] L. Ovesen,et al. A simple technique for predicting maintenance dosage of warfarin — Is it better than empirical dosing? , 1989, European Journal of Clinical Pharmacology.
[11] D. Mungall,et al. Effect of using warfarin plasma concentrations in Bayesian forecasting of prothrombin-time response. , 1987, Clinical pharmacy.
[12] D. Mungall,et al. Pharmacodynamics of Warfarin at Steady State , 1987, Therapeutic drug monitoring.
[13] A. Breckenridge,et al. Enantiomers of warfarin and vitamin K1 metabolism. , 1986, British journal of clinical pharmacology.
[14] N. Holford. Clinical Pharmacokinetics and Pharmacodynamics of Warfarin , 1986, Clinical pharmacokinetics.
[15] Silvana,et al. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. , 1986, The Journal of clinical investigation.
[16] M. Rowland,et al. Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine. , 1984, Journal of pharmaceutical sciences.
[17] L B Sheiner,et al. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. , 1982, Journal of pharmaceutical sciences.
[18] T J O'Leary,et al. Evaluation of a computer‐assisted method for individualized anticoagulation: Retrospective and prospective studies with a pharmacodynamic model , 1982, Clinical pharmacology and therapeutics.
[19] R. O'Reilly. Stereoselective Interaction of Sulfinpyrazone with Racemic Warfarin and Its Separated Enantiomorphs in Man , 1982, Circulation.
[20] R. Bell,et al. Inhibition by warfarin enantiomers of prothrombin synthesis, protein carboxylation, and the regeneration of vitamin K from vitamin K epoxide. , 1981, Biochemical pharmacology.
[21] A. Breckenridge,et al. Kinetics of warfarin absorption in man , 1973, Clinical pharmacology and therapeutics.
[22] T. Theofanous,et al. Multiple-dose kinetics of oral anticoagulants: methods of analysis and optimized dosing. , 1973, Journal of pharmaceutical sciences.
[23] L B Sheiner,et al. Computer-aided long-term anticoagulation therapy. , 1969, Computers and biomedical research, an international journal.
[24] William J. Jusko,et al. Berichten , 2005, Pharmaceutisch weekblad.
[25] L. Aarons,et al. A comparison of the relative sensitivities of factor VII and prothrombin time measurements in detecting drug interactions with warfarin , 2004, European Journal of Clinical Pharmacology.
[26] D. Mungall,et al. Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation. , 1985, Therapeutic drug monitoring.